非编码RNA在泛血管疾病中的研究进展

doi:10.20223/j.cnki.1000-8535.2026.02.001

摘要/Abstract

摘要： 泛血管疾病（PVD）是一类以动脉粥样硬化为共同病理基础、累及心、脑、肾及外周血管系统的临床综合征,具有多血管床共病特征,发病率高、致残致死率大。非编码RNA（ncRNA）作为基因表达的重要调控因子,在PVD的发生发展中发挥关键作用。微小RNA（miRNA）、长链非编码RNA（lncRNA）、环状RNA（circRNA）等ncRNA通过调节炎症反应、内皮功能、血管重塑、代谢稳态等多路径参与PVD的病理过程,并展现出时空特异性和双向调控特征。最新研究揭示ncRNA在临床中的诊断预测及靶向干预潜力,包括外泌体载体及circRNA递送系统等新策略。此外,中医药通过调控ncRNA网络,干预血瘀、痰浊等证型相关通路,体现中西医结合治疗的系统优势。本文系统综述了ncRNA在PVD中的作用机制与研究进展,强调其在精准诊疗与转化研究中的应用前景,并指出未来需加强基础与临床协同、推进个体化干预策略的落地实施。

关键词: 非编码RNA, 泛血管疾病, 动脉粥样硬化

Abstract: Panvascular diseases（PVD）are a group of clinical syndromes characterized by atherosclerosis as a common pathological foundation,involving heart,brain,kidneys,and peripheral vascular systems．These diseases often exhibit multi-vascular bed comorbidities and are associated with high incidence,disability,and mortality rates．Non-coding RNAs（ncRNAs）,as key regulators of gene expression,play a crucial role in the onset and progression of PVD．Various types of ncRNAs—including microRNAs（miRNAs）,long non-coding RNAs（lncRNAs）,and circular RNAs（circRNAs）—are involved in the pathological processes of PVD through multiple pathways,such as modulation of inflammatory responses,endothelial function,vascular remodeling,and metabolic homeostasis,exhibiting spatiotemporal specificity and bidirectional regulatory effects．Recent studies have highlighted the potential of ncRNAs in clinical diagnosis,prognosis,and targeted therapy,with novel strategies including exosome-based delivery and circRNA-targeting systems．In addition,traditional Chinese medicine（TCM）exerts regulatory effects on ncRNA networks to intervene in syndrome-specific pathways,such as those related to blood stasis and phlegm-dampness,reflecting the systemic advantages of integrating TCM with Western medicine．This review systematically summarizes the regulatory mechanisms and research progress of ncRNAs in PVD,emphasizes their potential in precision medicine and translational research,and proposes the need to strengthen collaboration between basic and clinical studies to facilitate the implementation of personalized therapeutic strategies．

Key words: non-coding RNA, panvascular diseases, atherosclerosis

孙钰洺, 宫丽鸿, 肖福龙, 李越. 非编码RNA在泛血管疾病中的研究进展[J]. 广州医药, 2026, 57(2): 122-132.

SUN Yuming, GONG Lihong, XIAO Fulong, LI Yue. Research progress of non-coding RNAs in panvascular diseases[J]. Guangzhou Medical Journal, 2026, 57(2): 122-132.

参考文献

[1] WONG M,DAI Y,GE J.Pan-vascular disease:What we have done in the past and what we can do in the future[J].Cardiol Plus,2024,9(1):1-5.
[2] 中国医师协会心血管内科医师分会.泛血管疾病抗栓治疗中国专家共识(2024版)[J].中华医学杂志,2024,104(12):906-923.
[3] ZHOU X,YU L,ZHAO Y,et al.Panvascular medicine:An emerging discipline focusing on atherosclerotic diseases[J].Eur Heart J,2022,43(43):4528-4531.
[4] ZHANG Y,ZHANG J,XU Z,et al.Regulation of NcRNA-protein binding in diabetic foot[J].Biomed Pharmacother,2023(160):114361.
[5] KE X,LIAO Z,LUO X,et al.Endothelial colony-forming cell-derived exosomal miR-21-5p regulates autophagic flux to promote vascular endothelial repair by inhibiting SIPL1A2 in atherosclerosis[J].Cell Commun Signal,2022,20(1):30.
[6] ZHANG L,YANG H,LI W J,et al.LncRNA MALAT1 promotes OGD-induced apoptosis of brain microvascular endothelial cells by sponging miR-126 to repress PI3K/Akt signaling pathway[J].Neurochem Res,2020,45(9):2091-2099.
[7] 中国医师协会中西医结合分会心血管专业委员会,中华中医药学会心血管病分会.动脉粥样硬化中西医防治专家共识(2021年)[J].中国中西医结合杂志,2022,42(3):287-293.
[8] SOLTANI S,ZANDI M.miR-200c-3p upregulation and ACE2 downregulation via bacterial LPS and LTA as interesting aspects for COVID-19 treatment and immunity[J].Mol Biol Rep,2021,48(7):5809-5810.
[9] HE Z,ZHONG Y,REGMI P,et al.Exosomal long non-coding RNA TRPM2-AS promotes angiogenesis in gallbladder cancer through interacting with PABPC1 to activate NOTCH1 signaling pathway[J].Mol Cancer,2024,23(1):65.
[10] SRIRAM K,LUO Y,YUAN D,et al.Vascular regulation by super enhancer-Derived LINC00607[J].Front Cardiovasc Med,2022(9):881916.
[11] LU X,YANG B,YANG H,et al.MicroRNA-320b modulates cholesterol efflux and atherosclerosis[J].J Atheroscler Thromb,2022,29(2):200-220.
[12] INFANTE-MENÉNDEZ J,LÓPEZ-PASTOR A R,GONZÁLEZ-LÓPEZ P,et al.The interplay between oxidative stress and miRNAs in obesity-associated hepatic and vascular complications[J].Antioxidants(Basel),2020,9(7):607.
[13] YU J,WANG W,YANG J,et al.LncRNA PSR regulates vascular remodeling through encoding a novel protein arteridin[J].Circ Res,2022,131(9):768-787.
[14] 王凤林,谢宝栋.microRNA在冠心病中的研究进展[J].心血管康复医学杂志,2024,33(2):252-255.
[15] SOTHIVELR V,HASAN M Y,MOHD SAFFIAN S,et al.Revisiting miRNA-21 as a therapeutic strategy for myocardial infarction:A systematic review[J].J Cardiovasc Pharmacol,2022,80(3):393-406.
[16] HUANG R,HUANG Y,ZENG G,et al.Ursodeoxycholic acid inhibits intimal hyperplasia,vascular smooth muscle cell excessive proliferation,migration via blocking miR-21/PTEN/AKT/mTOR signaling pathway[J].Cell Cycle,2020,19(8):918-932.
[17] PEI X,WEN Y,CUI F,et al.lncRNA CASC7 regulates pathological progression of ox-LDL-stimulated atherosclerotic cell models via sponging miR-21 and regulating PI3K/Akt and TLR4/NF-κB signaling pathways[J].Aging(Albany NY),2021,13(23):25408-25425.
[18] LIU Y,HE M,YUAN Y,et al.Neutrophil-membrane-coated biomineralized metal-organic framework nanoparticles for atherosclerosis treatment by targeting gene silencing[J].ACS Nano,2023,17(8):7721-7732.
[19] RUAN Z,CHU T,WU L,et al.miR-155 inhibits oxidized low-density lipoprotein-induced apoptosis in different cell models by targeting the p85α/AKT pathway[J].J Physiol Biochem,2020,76(2):329-343.
[20] PENG Q,YIN R,ZHU X,et al.miR-155 activates the NLRP3 inflammasome by regulating the MEK/ERK/NF-κB pathway in carotid atherosclerotic plaques in ApoE-/- mice[J].J Physiol Biochem,2022,78(2):365-375.
[21] ZHELANKIN A V,STONOGINA D A,VASILIEV S V,et al.Circulating extracellular miRNA analysis in patients with stable CAD and acute coronary syndromes[J].Biomolecules,2021,11(7):962.
[22] 林红丽,张雪菲,彭慧,等.microRNA-29a与冠心病心绞痛患者血管内皮损伤及斑块不稳定性的相关性[J].中国现代医学杂志,2023,33(17):84-88.
[23] POLYAKOVA E A,ZARAISKII M I,MIKHAYLOV E N,et al.Association of myocardial and serum miRNA expression patterns with the presence and extent of coronary artery disease:A cross-sectional study[J].Int J Cardiol,2021(322):9-15.
[24] HAN Y C,XIE H Z,LU B,et al.Effect of berberine on global modulation of lncRNAs and mRNAs expression profiles in patients with stable coronary heart disease[J].BMC Genomics,2022,23(1):400.
[25] SHI Y,LI Z,LI K,et al.miR-155-5p accelerates cerebral ischemia-reperfusion inflammation injury and cell pyroptosis via DUSP14/ TXNIP/NLRP3 pathway[J].Acta Biochim Pol,2022,69(4):787-793.
[26] SONG Y,SHI R,LIU Y,et al.M2 microglia extracellular vesicle miR-124 regulates neural stem cell differentiation in ischemic stroke via AAK1/NOTCH[J].Stroke,2023,54(10):2629-2639.
[27] 耿炜,周涛,李晓鹏,等.出血性脑卒中患者血清miR-217-5p表达及临床意义[J].心脑血管病防治,2023,23(11):18-22,31.
[28] MAZZOLAI L,TEIXIDO-TURA G,LANZI S,et al.2024 ESC Guidelines for the management of peripheral arterial and aortic diseases[J].Eur Heart J,2024,45(36):3538-3700.
[29] SIELAND J,NIEDERER D,ENGEROFF T,et al.Changes in miRNA expression in patients with peripheral arterial vascular disease during moderate- and vigorous-intensity physical activity[J].Eur J Appl Physiol,2023,123(3):645-654.
[30] BORRI M,JACOBS M E,CARMELIET P,et al.Endothelial dysfunction in the aging kidney[J].Am J Physiol Renal Physiol,2025,328(4):F542-F562.
[31] ZHANG C,ZHAO H,YAN Y,et al.LncRNA evf-2 exacerbates podocyte injury in diabetic nephropathy by inducing cell cycle re-entry and inflammation through distinct mechanisms triggered by hnRNPU[J].Adv Sci(Weinh),2024,11(47):e2406532.
[32] ZHAO S,LI W,YU W,et al.Exosomal miR-21 from tubular cells contributes to renal fibrosis by activating fibroblasts via targeting PTEN in obstructed kidneys[J].Theranostics,2021,11(18):8660-8673.
[33] FARAHANI R A,ZHU X Y,TANG H,et al.Metabolic syndrome alters the cargo of mitochondria-related microRNAs in swine mesenchymal stem cell-derived extracellular vesicles,impairing their capacity to repair the stenotic kidney[J].Stem Cells Int,2020(2020):8845635.
[34] PETERS L J F,FLOEGE J,BIESSEN E A L,et al.MicroRNAs in chronic kidney disease:Four candidates for clinical application[J].Int J Mol Sci,2020,21(18):6547.
[35] SEQUEIRA-LOPEZ M L S,GOMEZ R A.Renin cells,the kidney,and hypertension[J].Circ Res,2021,128(7):887-907.
[36] DU J,HAN R,LI Y,et al.LncRNA HCG11/miR-26b-5p/QKI5 feedback loop reversed high glucose-induced proliferation and angiogenesis inhibition of HUVECs[J].J Cell Mol Med,2020,24(24):14231-14246.
[37] GONG Y P,ZHANG Y W,SU X Q,et al.Inhibition of long noncoding RNA MALAT1 suppresses high glucose-induced apoptosis and inflammation in human umbilical vein endothelial cells by suppressing the NF-κB signaling pathway[J].Biochem Cell Biol,2020,98(6):669-675.
[38] CHANG F,WANG C,ZHENG P,et al.Malat1 promotes macrophage-associated inflammation by increasing PPAR-γ methylation through binding to EZH2 in acute myocardial infarction[J].Int Immunopharmacol,2023(123):110695.
[39] XIANG D,JIANG L,YUAN Q,et al.Leukocyte-specific morrbid promotes leukocyte differentiation and atherogenesis[J].Research(Wash D C),2023(6):0187.
[40] GHIASVAND T,KARIMI J,KHODADADI I,et al.The interplay of LDLR,PCSK9,and lncRNA- LASER genes expression in coronary artery disease:Implications for therapeutic interventions[J].Prostaglandins Other Lipid Mediat,2025(177):106969.
[41] FANG H,LI H F,PAN Q,et al.Long noncoding RNA H19 overexpression protects against hypoxic-ischemic brain damage by inhibiting miR-107 and up-regulating vascular endothelial growth factor[J].Am J Pathol,2021,191(3):503-514.
[42] PAN Y,XIN W,WEI W,et al.Knockdown of NEAT1 prevents post-stroke lipid droplet agglomeration in microglia by regulating autophagy[J].Cell Mol Life Sci,2024,81(1):30.
[43] TANG X,LUO Y,YUAN D,et al.Long noncoding RNA LEENE promotes angiogenesis and ischemic recovery in diabetes models[J].J Clin Invest,2023,133(3):e161759.
[44] HUANG L,YE Y,SUN Y,et al.LncRNA H19/miR-107 regulates endothelial progenitor cell pyroptosis and promotes flow recovery of lower extremity ischemia through targeting FADD[J].Biochim Biophys Acta Mol Basis Dis,2024,1870(7):167323.
[45] DU L,LU Y,WANG J,et al.LncRNA KIFAP3-5:1 inhibits epithelial-mesenchymal transition of renal tubular cell through PRRX1 in diabetic nephropathy[J].Cell Biol Toxicol,2024,40(1):47.
[46] FU W,TIAN X,LIU L,et al.Long noncoding RNA PR11-387H17.6 as a potential novel diagnostic biomarker of atherosclerotic renal artery stenosis[J].Ren Fail,2021,43(1):1188-1197.
[47] SU P P,LIU D W,ZHOU S J,et al.Down-regulation of Risa improves podocyte injury by enhancing autophagy in diabetic nephropathy[J].Mil Med Res,2022,9(1):23.
[48] WANG Z,LIU Z,YANG Y,et al.Identification of biomarkers and pathways in hypertensive nephropathy based on the ceRNA regulatory network[J].BMC Nephrol,2020,21(1):476.
[49] NISHITA-HIRESHA V,VARSHA R,JAYASURIYA R,et al.The role of circRNA-miRNA-mRNA interaction network in endothelial dysfunction[J].Gene,2023(851):146950.
[50] HUANG J G,TANG X,WANG J J,et al.A circular RNA,circUSP36,accelerates endothelial cell dysfunction in atherosclerosis by adsorbing miR-637 to enhance WNT4 expression[J].Bioengineered,2021,12(1):6759-6770.
[51] CHEN W,XU J,WU Y,et al.The potential role and mechanism of circRNA/miRNA axis in cholesterol synthesis[J].Int J Biol Sci,2023,19(9):2879-2896.
[52] PAN Z,LV J,ZHAO L,et al.CircARCN1 aggravates atherosclerosis by regulating HuR-mediated USP31 mRNA in macrophages[J].Cardiovasc Res,2024,120(13):1531-1549.
[53] YANG Z,HUANG C,WEN X,et al.Circular RNA circ-FoxO3 attenuates blood-brain barrier damage by inducing autophagy during ischemia/reperfusion[J].Mol Ther,2022,30(3):1275-1287.
[54] YANG L,HAN B,ZHANG Z,et al.Extracellular vesicle-mediated delivery of circular RNA SCMH1 promotes functional recovery in rodent and nonhuman primate ischemic stroke models[J].Circulation,2020,142(6):556-574.
[55] CHEN J,LI X,LIU H,et al.Bone marrow stromal cell-derived exosomal circular RNA improves diabetic foot ulcer wound healing by activating the nuclear factor erythroid 2-related factor 2 pathway and inhibiting ferroptosis[J].Diabet Med,2023,40(7):e15031.
[56] LIU J,ZHANG Y,LIU C,et al.A single dose of VEGF-A circular RNA sustains in situ long-term expression of protein to accelerate diabetic wound healing[J].J Control Release,2024(373):319-335.
[57] LIU X,JIANG L,ZENG H,et al.Circ-0000953deficiency exacerbates podocyte injury and autophagy disorder by targetingMir665-3p-Atg4bin diabetic nephropathy[J].Autophagy,2024,20(5):1072-1097.
[58] ZHANG K,LI Y,HUANG Y,et al.PiRNA in cardiovascular disease:Focus on cardiac remodeling and cardiac protection[J].J Cardiovasc Transl Res,2023,16(4):768-777.
[59] HE T,PU J,GE H,et al.Elevated circulating LncRNA NORAD fosters endothelial cell growth and averts ferroptosis by modulating the miR-106a/CCND1 axis in CAD patients[J].Sci Rep,2024,14(1):24223.
[60] RAY K K,TROQUAY R P T,VISSEREN F L J,et al.Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol(ORION-3):Results from the 4-year open-label extension of the ORION-1 trial[J].Lancet Diabetes Endocrinol,2023,11(2):109-119.
[61] ZHAN L,CHEN M,PANG T,et al.Attenuation of Piwil2 induced by hypoxic postconditioning prevents cerebral ischemic injury by inhibiting CREB2 promoter methylation[J].Brain Pathol,2023,33(1):e13109.
[62] SUN H,LI S,XU Z,et al.SNHG15 is a negative regulator of inflammation by mediating TRAF2 ubiquitination in stroke-induced immunosuppression[J].J Neuroinflammation,2022,19(1):1.
[63] ZONG T,YANG Y,ZHAO H,et al.tsRNAs:Novel small molecules from cell function and regulatory mechanism to therapeutic targets[J].Cell Prolif,2021,54(3):e12977.
[64] 才振国,杨艳丽,李竹英,等.中医药调控心脏疾病中长链非编码RNA研究进展[J].河北中医,2022,44(8):1391-1396,1400.
[65] 周霞辉,罗晓欣,周曼丽,等.冠状动脉粥样硬化性心脏病血瘀证表观遗传学研究进展[J].中国中医药信息杂志,2022,29(6):148-152.
[66] SU W,LV M,WANG D,et al.Tanshinone IIA alleviates traumatic brain injury by reducing ischemia-reperfusion via the miR-124-5p/FoxO1 axis[J].Mediators Inflamm,2024(2024):7459054.
[67] LI Y,YE Q,LI J,et al.Exploring the mechanism of Taohong Siwu Decoction in treating ischemic stroke injury via the circDnajc1/miR-27a-5p/C1qc signaling axis[J].Phytomedicine,2025(136):156305.
[68] FROLDI G,RAGAZZI E.Selected plant-derived polyphenols as potential therapeutic agents for peripheral artery disease:Molecular mechanisms,efficacy and safety[J].Molecules,2022,27(20):7110.
[69] 倪英群,李居一,黄日龙,等.气阴两虚夹瘀型2型糖尿病患者外周血LncRNA TUG 1与血管病变标志因子的相关性[J].辽宁中医杂志,2024,51(5):23-25.
[70] ZHANG Y,DENG Y,YANG Y,et al.Polysaccharides from Dendrobium officinale delay diabetic kidney disease interstitial fibrosis through LncRNA XIST/TGF-β1[J].Biomed Pharmacother,2024(175):116636.
[71] LI C,ZHANG S,CHEN X,et al.Farnesoid X receptor activation inhibits TGFBR1/TAK1-mediated vascular inflammation and calcification via miR-135a-5p[J].Commun Biol,2020,3(1):327.